[{"id":"41b868a7-e7be-446b-8235-fde40165cb18","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292898","created_at":"2022-03-23T13:53:39.110Z","updated_at":"2024-07-02T16:35:03.931Z","phase":"Phase 1","brief_title":"A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05292898","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LCAR-AIO"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-14"},{"id":"56c5cad0-d1ef-422d-be11-4bf042346cca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05318963","created_at":"2022-04-08T20:52:42.049Z","updated_at":"2024-07-02T16:35:41.159Z","phase":"Phase 1","brief_title":"Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT05318963","lead_sponsor":"Qiu Lugui","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LCAR-AIO"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-08-03"}]